- Home
- SUUN vs IMMX Comparison
SUUN vs IMMX Comparison
Compare SUUN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- IMMX
- Stock Information
- Founded
- SUUN 2013
- IMMX 2014
- Country
- SUUN Canada
- IMMX United States
- Employees
- SUUN N/A
- IMMX N/A
- Industry
- SUUN
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- SUUN
- IMMX Health Care
- Exchange
- SUUN Nasdaq
- IMMX Nasdaq
- Market Cap
- SUUN 68.9M
- IMMX 82.6M
- IPO Year
- SUUN N/A
- IMMX 2021
- Fundamental
- Price
- SUUN $1.69
- IMMX $3.90
- Analyst Decision
- SUUN Strong Buy
- IMMX Strong Buy
- Analyst Count
- SUUN 2
- IMMX 1
- Target Price
- SUUN $5.00
- IMMX $8.00
- AVG Volume (30 Days)
- SUUN 401.8K
- IMMX 758.3K
- Earning Date
- SUUN 11-13-2025
- IMMX 11-07-2025
- Dividend Yield
- SUUN N/A
- IMMX N/A
- EPS Growth
- SUUN N/A
- IMMX N/A
- EPS
- SUUN N/A
- IMMX N/A
- Revenue
- SUUN $30,451,073.00
- IMMX N/A
- Revenue This Year
- SUUN $86.31
- IMMX N/A
- Revenue Next Year
- SUUN $24.16
- IMMX N/A
- P/E Ratio
- SUUN N/A
- IMMX N/A
- Revenue Growth
- SUUN N/A
- IMMX N/A
- 52 Week Low
- SUUN $1.23
- IMMX $1.34
- 52 Week High
- SUUN $6.43
- IMMX $4.00
- Technical
- Relative Strength Index (RSI)
- SUUN 43.70
- IMMX 79.93
- Support Level
- SUUN $1.71
- IMMX $2.31
- Resistance Level
- SUUN $1.99
- IMMX $2.82
- Average True Range (ATR)
- SUUN 0.19
- IMMX 0.33
- MACD
- SUUN -0.03
- IMMX 0.12
- Stochastic Oscillator
- SUUN 3.65
- IMMX 94.08
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.